Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Preaxia Health Care Payment Systems (PAXH) Research & Development (2019 - 2025)

Preaxia Health Care Payment Systems' Research & Development history spans 7 years, with the latest figure at $391263.0 for Q3 2025.

  • For Q3 2025, Research & Development changed N/A year-over-year to $391263.0; the TTM value through Aug 2025 reached $391263.0, up 9415.15%, while the annual FY2024 figure was $5632.0, 13.73% down from the prior year.
  • Research & Development for Q3 2025 was $391263.0 at Preaxia Health Care Payment Systems, up from -$503.0 in the prior quarter.
  • Across five years, Research & Development topped out at $391263.0 in Q3 2025 and bottomed at -$503.0 in Q2 2024.
  • The 5-year median for Research & Development is $2081.0 (2021), against an average of $28924.1.
  • The largest YoY upside for Research & Development was 556.6% in 2024 against a maximum downside of 138.31% in 2024.
  • A 5-year view of Research & Development shows it stood at $2073.0 in 2021, then fell by 24.12% to $1573.0 in 2022, then surged by 38.53% to $2179.0 in 2023, then tumbled by 123.08% to -$503.0 in 2024, then surged by 77885.88% to $391263.0 in 2025.
  • Per Business Quant, the three most recent readings for PAXH's Research & Development are $391263.0 (Q3 2025), -$503.0 (Q2 2024), and $2436.0 (Q1 2024).